^
    Back
    Association details:
    Biomarker:ALK rearrangement
    Cancer:Lung Cancer
    Drug:Alecensa (alectinib) (ALK inhibitor) +
    YHO-1701 (STAT3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    NPJ Precis Oncol
    Title:

    STAT3 inhibition suppresses adaptive survival of ALK-rearranged lung cancer cells through transcriptional modulation of apoptosis

    Published date:
    02/28/2022
    Excerpt:
    STAT3 inhibition effectively suppressed the adaptive survival of ALK-rearranged lung cancer cells by enhancing ALK inhibition-induced apoptosis…. In xenograft study, the combination of YHO-1701 (STAT3 inhibitor) and alectinib significantly suppressed tumor regrowth after treatment cessation with near tumor remission compared with alectinib alone. Hence, this study provides new insights into combined therapeutic strategies for patients with ALK-rearranged lung cancer.
    DOI:
    10.1038/s41698-022-00254-y